Given the observation of an acquired MYC amplification upon rapidly progressive disease while receiving anti-PD-1 therapy following an initial partial response, we proceeded to characterize clinical-pathologic features of MYC amplified HNSCC from our internal dataset, performed RNA-Seq of the paired samples with and without MYC amplification from our case study, and analyzed transcriptomic data of MYC amplified cases obtained from TCGA-HNSC dataset. This evidence concerns the gene MYC and head and neck squamous cell carcinoma.